
Renal Cell Carcinoma
Latest News
Video Series

Latest Videos
Shorts

CME Content
More News

During a live event, Thomas Hutson, DO, PharmD, PhD, and participants discussed current best practice with adjuvant IO post-nephrectomy.

The phase 3 LITESPARK-012 trial failed to meet primary end points of PFS/OS for adding belzutifan or quavonlimab to the standard pembro/lenvatinib doublet.

Darlifarnib may enable the rechallenging of patients with cabozantinib in a combination context for patients with clear cell renal cell carcinoma.

Naomi Haas, MD, shares her insights on the rapidly shifting landscape of adjuvant and neoadjuvant therapies in renal cell carcinoma.

Hutson discusses 3 key clinical trials in RCC: CheckMate 9ER, KEYNOTE-426, and the CLEAR study.

Dr Naomi Haas discusses the feasibility of neoadjuvant therapy in RCC, highlighting the PROSPER trial's results and its role in treating unresectable disease.

Dr. Pavlos Msaouel notes that platinum-based chemotherapy remains a stalwart treatment but immunotherapies lead to less-than-optimal results.

Learn the warning signs of renal medullary carcinoma—sickle cell trait, right-sided mass—and why INI1 testing changes therapy and survival.

Immunohistochemistry is the gold standard for diagnosing renal medullary carcinoma, as genetic sequencing often misses key SMARCB1 alterations.

KEYNOTE-564 follow-up shows OS and DFS gains with adjuvant pembrolizumab in high-risk ccRCC, plus guidance on relapse after therapy.

As one of the rare subtypes of renal cell carcinoma, renal medullary carcinoma presents with some distinct signs: male, Black, between 12 and 45 years of age, sickle cell trait, and a mass in the right kidney.

Use of the ProSense Cryoablation System in patients with kidney cancer resulted in an 83.9% recurrence-free rate among 112 patients in the ICESECRET clinical trial (NCT02399124).

During a live event, the benefit of adding nivolumab (Opdivo) to tivozanib (Fotivda) in the second-line setting was discussed by David Braun, MD, and participants.

Deepak Kilari, MD, shared his insights on recent trials in renal cell carcinoma presented at the 2026 ASCO Genitourinary Cancers Symposium.


LITESPARK-011 demonstrated improved progression-free survival with the combination of belzutifan plus lenvatinib vs cabozantinib.

The CYTOSHRINK trial showed that incorporating stereotactic body radiation therapy (SBRT) with ipilimumab and nivolumab did not enhance progression-free survival and resulted in a shorter median PFS compared to immunotherapy alone for advanced renal cell carcinoma.

Long-term CheckMate 9ER results show deeper tumor shrinkage with cabozantinib plus nivolumab and predicts longer survival and durable responses in advanced renal cell carcinoma.

The combination of durvalumab and tremelimumab improved disease-free survival compared with active monitoring, but efficacy came with increased toxicity.

Using the best medication available in the frontline setting of RCC leads to optimal results.

Clinical validation results show changes in methylated circulating tumor DNA (ctDNA) measured prior to treatment initiation and before cycle 3 of therapy were strongly associated with objective response and clinical benefit.

The LITESPARK-024 trial showed a manageable safety profile for belzutifan and palbociclib in advanced RCC, but the response rate did not exceed that of historical single-agent belzutifan.

Findings from the phase 3 LITESPARK-011 trial favored belzutifan/lenvatinib vs cabozantinib in PFS and ORR.











































